Insider Buying: Bluejay Diagnostics (NASDAQ:BJDX) Director Buys 12,500 Shares of Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Fred Zeidman purchased 12,500 shares of Bluejay Diagnostics stock in a transaction that occurred on Saturday, March 14th. The shares were purchased at an average price of $2.00 per share, for a total transaction of $25,000.00. Following the transaction, the director directly owned 12,500 shares in the company, valued at $25,000. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Bluejay Diagnostics Stock Performance

Shares of NASDAQ BJDX traded up $0.05 during trading hours on Monday, hitting $1.72. 34,940 shares of the stock were exchanged, compared to its average volume of 155,600. The company has a market cap of $1.77 million, a PE ratio of -0.15 and a beta of 0.72. The company’s fifty day simple moving average is $1.90 and its two-hundred day simple moving average is $3.24. Bluejay Diagnostics, Inc. has a 1-year low of $1.63 and a 1-year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. 18.47% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.